Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432235 · ClinicalTrials.gov registry record · Phase 1
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by ADC Therapeutics S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT02432235 is a Phase 1 study that has completed, run by ADC Therapeutics S.A.. The registered enrollment target is 133 participants.
The verdict
NCT02432235, a Phase 1 study, has completed, sponsored by ADC Therapeutics S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
This study evaluates camidanlumab tesirine in participants with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma.
Interventions
- DRUG Camidanlumab tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2015-10-05 |
| Est. Completion | 2019-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02432235
The ClinicalTrials.gov registry entry for NCT02432235 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Camidanlumab tesirine is the first listed.
NCT02432235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02432235 about?
NCT02432235 is a clinical study titled "Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma". This study evaluates camidanlumab tesirine in participants with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma.
What is the current status of trial NCT02432235?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2015-10-05. Estimated completion is 2019-10-24.
What interventions are being tested in trial NCT02432235?
The interventions under investigation include: Camidanlumab tesirine (DRUG).
Who is sponsoring clinical trial NCT02432235?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.